{"id":570,"date":"2026-01-23T00:25:07","date_gmt":"2026-01-23T00:25:07","guid":{"rendered":"https:\/\/kishiwada.tokushukai.or.jp\/en\/?page_id=570"},"modified":"2026-04-11T03:56:17","modified_gmt":"2026-04-11T03:56:17","slug":"bladder-cancer","status":"publish","type":"page","link":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/urology\/bladder-cancer\/","title":{"rendered":"Bladder Cancer"},"content":{"rendered":"

<\/p>\n

\n
\n

<\/p>\n

\n
\n
Procedure volume (2023)<\/div>\n
TURBT: 93 endoscopic bladder tumour resections<\/div>\n<\/p><\/div>\n
\n
Surgical approach<\/div>\n
Endoscopic surgery through the urethra without external incision<\/div>\n<\/p><\/div>\n
\n
Treatment approach<\/div>\n
Bladder preservation where clinically appropriate, with risk-based follow-up<\/div>\n<\/p><\/div>\n
\n
Clinical leadership<\/div>\n
Managed within a specialist urologic oncology programme<\/div>\n<\/p><\/div>\n<\/p><\/div>\n

\n Bladder cancer is often first identified through haematuria or incidental imaging findings.
\n At Kishiwada Tokushukai Hospital, many bladder tumours are managed endoscopically,
\n with 93 transurethral resections of bladder tumour (TURBT) performed in 2023.
\n Treatment planning is based on tumour stage, grade, and pathological findings,
\n with preservation of bladder function whenever clinically appropriate.\n <\/p>\n

\n
\n
\n

What is bladder cancer?<\/h2>\n<\/p><\/div>\n
\n

\n Bladder cancer arises from the inner lining of the bladder.
\n Many cases are non-muscle-invasive at diagnosis, meaning the tumour remains confined
\n to the superficial layers and can often be treated endoscopically.
\n Muscle-invasive disease requires more extensive treatment planning.\n <\/p>\n

\n Because bladder cancer may recur after treatment, structured surveillance
\n is an important part of long-term management.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n
\n

When consultation is recommended<\/h2>\n<\/p><\/div>\n
\n
\n
    \n
  • Visible or microscopic blood in the urine (haematuria)<\/li>\n
  • Abnormal bladder findings on ultrasound, CT, or MRI<\/li>\n
  • Suspicion of a bladder tumour requiring cystoscopic evaluation<\/li>\n
  • Confirmed bladder cancer requiring treatment planning or follow-up<\/li>\n
  • Surveillance cystoscopy after previous treatment<\/li>\n<\/ul><\/div>\n

    \n Previous urinalysis results, imaging reports, cystoscopy findings, and pathology reports
    \n are helpful if available. Overseas records are accepted.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

    \n
    \n

    Endoscopic surgery \u2014 TURBT<\/h2>\n<\/p><\/div>\n
    \n

    \n Transurethral resection of bladder tumour (TURBT) is performed endoscopically
    \n through the urethra, without a skin incision.
    \n The procedure serves both diagnostic and therapeutic purposes:
    \n tumour tissue is removed and examined pathologically to determine stage, grade,
    \n and risk of recurrence.\n <\/p>\n

    \n In 2023, 93 TURBT procedures were performed at this hospital.
    \n Length of stay depends on tumour characteristics and overall clinical condition.\n <\/p>\n

    \n Procedure time and hospitalisation vary according to the size, number,
    \n and location of the tumours within the bladder.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

    \n
    \n

    Treatment planning and bladder preservation<\/h2>\n<\/p><\/div>\n
    \n

    \n Further treatment after TURBT depends on pathological findings and risk classification.
    \n For low-risk disease, surveillance cystoscopy alone may be sufficient.
    \n For higher-risk or recurrent tumours, intravesical therapy or repeat resection may be recommended.
    \n Muscle-invasive disease may require radical cystectomy.\n <\/p>\n

    \n Where appropriate, bladder-preserving strategies are prioritised.
    \n Treatment options and expected outcomes are explained before decisions are made.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

    \n
    \n

    Follow-up and long-term care<\/h2>\n<\/p><\/div>\n
    \n

    \n Follow-up for bladder cancer usually includes periodic cystoscopy and urine testing
    \n to detect recurrence at an early stage.
    \n The schedule and duration of follow-up depend on the individual risk category.
    \n For international patients, follow-up coordination can be supported
    \n through the International Medical Support Office.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n

    <\/p>\n

    \n
    \n

    Appointment<\/h2>\n<\/p><\/div>\n
    \n

    \n Appointments are required in principle. A referral letter from another medical institution is recommended but not mandatory.\n <\/p>\n

    \n For appointment requests and language support, please see the
    \n Urology department<\/a> page.\n <\/p>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/section>\n